1. Heart failure https://www.clinicalkey.com Accessed May 15, 2013.
2. Elliott M. Antman, and Marc S. Sabatine. Cardiovascular Therapeutics: A
Companion to Braunwald's Heart Disease , Fourth Edition. Chapter 14 Strategies for Management of Acute Decompensated Heart Failure. 281-306.
https://www.clinicalkey.com Accessed May 15, 2013.
3. Management of acute decompensated heart failure Larry A. Allen, Christopher M.
O'Connor CMAJ March 13, 2007 vol. 176(6) 797-805
4. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline . J Card Fail. 2010;16:e1-194
5. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation . Circulation. 2009;119:1977-2016 6. Markku S. Nieminen, Dirk Brutsaert, Kenneth Dickstein, Helmut Drexler, Ferenc
Follath, EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. European Heart Journal (2006) 27, 2725–2736
7. 藥物、醫療器材、化妝品許可證查詢作業. 行政院衛生署.
http://www.doh.gov.tw/CHT2006/DM/DM1_p01.aspx?class_no=471&now_fod_l ist_no=471&level_no=1&doc_no=76642. Accessed May 13, 2013.
8. ATC/DDD Index 2012. WHO Collaborating Centre for Drug Statistics
Methodology. http://www.whocc.no/atc_ddd_index/. Published 2012. Accessed May 13, 2013.
9. 中央健保局 藥品給付規定
http://www.nhi.gov.tw/webdata/webdata.aspx?menu=21&menu_id=713&WD_ID
=849&webdata_id=2919 Accessed May 13, 2013.
10. Lissovoy G, Fraeman K, Teerlink JR, Mullahy J, Salon J, Sterz R, Durtschi A, Padley RJ. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study. Eur J Health Econ. 2010 Apr;11(2):185-93.
11. Iyisoy A., Ç elik T., Ç elik M., Buǧan B., Yaman H.Comparative effects of levosimendan and dobutamine infusion on p wave dispersion in patients with acute decompensated heart failure Turkish Journal of Medical Sciences 2010 40:5 (761-770)
12. Bergh C.H., Andersson B., Dahlström U., Forfang K., Kivikko M., Sarapohja T., Ullman B., Wikström G. Intravenous levosimendan vs. dobutamine in acute
decompensated heart failure patients on beta-blockers. European Journal of Heart Failure 2010 12:4 (404-410)
13. Alexandre Mebazaa, Markku S. Nieminen, Gerasimos S. Filippatos, John G.
Cleland, Jeffrey E. Salon, Roopal Thakkar, Robert J. Padley, Bidan Huang, and Alain Cohen-Solal. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on β-blockers in SURVIVE. Eur J Heart Fail. 2009 March; 11(3):
304–311.
14. Duygu H., Ozerkan F., Zoghi M., Nalbantgil S., Yildiz A., Akilli A., Akin M., Nazli C., Ergene O. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure. International Journal of Clinical Practice 2008 62:2 (228-233)
15. Fotbolcu H, Duman D. A promising new inotrope: levosimendan. Anadolu Kardiyol Derg. 2010 Apr;10(2):176-82.
16. Tong A.T., Rozner M.A. The role of nesiritide in heart failure
Expert Opinion on Drug Metabolism and Toxicology 2009 5:7 (823-834) 17. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for
patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
JAMA 2007;297(17):1883-91
18. Triposkiadis F, Parissis JT, Starling RC, Skoularigis J, Louridas G.Current drugs and medical treatment algorithms in the management of acute decompensated heart failure. Expert Opin Investig Drugs. 2009 Jun;18(6):695-707.
19. Ribeiro RA, Rohde LE, Polanczyk CA. Levosimendan in acute decompensated heart failure: systematic review and meta-analysis. Arq Bras Cardiol. 2010 Aug;95(2):230-7.
20. Anthony Delaney. Celia Bradford.John McCaffrey Sean M. Bagshaw. Richard Lee.
Levosimendan for the treatment of acute severe heart failure: A meta-analysis of randomised controlled trials. International Journal of Cardiology Volume 138,
Issue 3 , Pages 281-289, 4 February 2010
21. Gauthier N., Anselm A.H., Haddad H. New therapies in acute decompensated heart failure. Current Opinion in Cardiology 2008 23:2 (134-140)
22. Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, Guarracino F, Zangrillo A. Effects of levosimendan on mortality and
hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med.
2012 Feb;40(2):634-46.
23. Catherine L. Tacon, John McCaffrey, Anthony Delaney. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med published online:08 Dec. 2011
24. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP,
Mitrovic V, Abdalla M, Sandell EP, Lehtonen L; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study.
Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.
Lancet 2002; 360: 196–202
25. V. S. Moiseyev, P. Po˜ der, N. Andrejevs, M. Y. Ruda, A. P. Golikov, L. B.
Lazebnik, Z. D. Kobalava, L. A. Lehtonen, T. Laine, M. S. Nieminen and K. I.
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction--A randomized, placebo-controlled, double-blind study (RUSSLAN) . European Heart Journal (2002) 23, 1422–1432
26. 2012 Guidelines of the Taiwan Society of Cardiology (TSOC) for the Diagnosis and Treatment of Heart Failure. Acta Cardiol Sin 2012;28:161_195
27. Cleland JG, Takala A, Apajasalo M, Zethraeus N, Kobelt G. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
European journal of heart failure 2003; 5(1): 101-108.
28. de Lissovoy G, Fraeman K, Salon J, Chay Woodward T, Sterz R. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial. Journal of medical economics 2008; 11(3): 415-429.
29. de Lissovoy G, Fraeman K, Teerlink JR, et al. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study. The European journal of health economics : HEPAC : health economics in prevention and care 2010; 11(2):
185-193.
30. Fedele F, D'Ambrosi A, Bruno N, Caira C, Brasolin B, Mancone M.
Cost-effectiveness of levosimendan in patients with acute heart failure. Journal of cardiovascular pharmacology 2011; 58(4): 363-366.
附錄、經濟評估文獻搜尋紀錄
資料庫 查詢日期 關鍵字 篇數
NHS Center for Reviews and Dissemination
102 年 6 月 4 日 (levosimendan) limited to “NHS EED”
2
Cochrane Library 1800-2012
102 年 6 月 4 日 levosimendan
limited to “economic evaluation”
7 PubMed
1950-2012
102 年 6 月 4 日 #1 levosimendan
#2 ((economic) OR cost) OR cost-benefit
#3 #1 AND #2
1
EMBASE 1980-2012
102 年 6 月 4 日 'levosimendan'/exp AND 'cost'/exp AND [english]/lim
47